According to Enanta Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of 1.36.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 1.03 | -67.89% |
2022-12-31 | 3.22 | -19.38% |
2021-12-31 | 3.99 | 113.3% |
2020-12-31 | 1.87 | -26.3% |
2019-12-31 | 2.54 | -21.32% |
2018-12-31 | 3.23 | -8.74% |
2017-12-31 | 3.53 | 48.58% |
2016-12-31 | 2.38 | 1.29% |
2015-12-31 | 2.35 | -51.94% |
2014-12-31 | 4.89 | 5.25% |
2013-12-31 | 4.64 | |
2012-12-31 | N/A | |
2011-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.12 | 275.46% | ๐บ๐ธ USA |
Novartis NVS | 5.03 | 269.04% | ๐จ๐ญ Switzerland |
AbbVie ABBV | 27.2 | 1,893.19% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | 5.84 | 328.46% | ๐บ๐ธ USA |
Merck MRK | 8.83 | 547.47% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 3.08 | 126.05% | ๐บ๐ธ USA |